[go: up one dir, main page]

WO1996033282A3 - High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations - Google Patents

High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations Download PDF

Info

Publication number
WO1996033282A3
WO1996033282A3 PCT/US1996/005638 US9605638W WO9633282A3 WO 1996033282 A3 WO1996033282 A3 WO 1996033282A3 US 9605638 W US9605638 W US 9605638W WO 9633282 A3 WO9633282 A3 WO 9633282A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
recombinant retroviral
titer recombinant
vivo transduction
high titer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/005638
Other languages
French (fr)
Other versions
WO1996033282A2 (en
Inventor
Douglas J Jolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Priority to JP8531997A priority Critical patent/JPH11503916A/en
Priority to AU55682/96A priority patent/AU5568296A/en
Priority to EP96913061A priority patent/EP0871756A2/en
Publication of WO1996033282A2 publication Critical patent/WO1996033282A2/en
Publication of WO1996033282A3 publication Critical patent/WO1996033282A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods for the efficient ex vivo introduction of nucleic acid into T cells, non-dividing cells, and cells resistant to standard transduction techniques mediated by high titer recombinant retroviral preparations is described. The recombinant vector constructs carried by the recombinant retrovirus particles code for the production of one or more desired gene products from one or more corresponding genes of interest, at least one of the gene products having a therapeutic application. Upon re-introduction into a patient, the transduced cells produce a desired gene product in an amount sufficient to treat a particular disease state.
PCT/US1996/005638 1995-04-20 1996-04-19 High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations Ceased WO1996033282A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8531997A JPH11503916A (en) 1995-04-20 1996-04-19 Highly efficient ex vivo transduction of cells with high titer recombinant retrovirus preparations
AU55682/96A AU5568296A (en) 1995-04-20 1996-04-19 High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
EP96913061A EP0871756A2 (en) 1995-04-20 1996-04-19 High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42518095A 1995-04-20 1995-04-20
US08/425,180 1995-04-20

Publications (2)

Publication Number Publication Date
WO1996033282A2 WO1996033282A2 (en) 1996-10-24
WO1996033282A3 true WO1996033282A3 (en) 1996-12-12

Family

ID=23685512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005638 Ceased WO1996033282A2 (en) 1995-04-20 1996-04-19 High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations

Country Status (5)

Country Link
EP (1) EP0871756A2 (en)
JP (1) JPH11503916A (en)
AU (1) AU5568296A (en)
CA (1) CA2216871A1 (en)
WO (1) WO1996033282A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6114113A (en) * 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
US5994134A (en) † 1998-05-04 1999-11-30 Canji, Inc. Viral production process
RU2478711C1 (en) * 2011-12-19 2013-04-10 Открытое акционерное общество "Институт стволовых клеток человека" Method for providing higher effectiveness of viral transduction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022489A1 (en) * 1993-04-06 1994-10-13 Targeted Genetics Corporation Hybrid genes for use in the production of th-independent cytotoxic t cells
WO1994029438A1 (en) * 1993-06-11 1994-12-22 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
WO1995007358A1 (en) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022489A1 (en) * 1993-04-06 1994-10-13 Targeted Genetics Corporation Hybrid genes for use in the production of th-independent cytotoxic t cells
WO1994029438A1 (en) * 1993-06-11 1994-12-22 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
WO1995007358A1 (en) * 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. FERRARI ET AL.: "An in vivo modl of somatic cell gene therapy for human severe combined immunodeficiency", SCIENCE, vol. 251, 1991, pages 1363 - 1366, XP000381747 *
M.C. LEAVITT ET AL.: "Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes", HUMAN GENE THERAPY, vol. 5, 1994, pages 1115 - 1120, XP002012405 *
R.C. HOEBEN ET AL.: "Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haemopoietic progenitor cells", THROMBOSIS AND HAEMOSTASIS, vol. 67, 1992, pages 341 - 345, XP002012407 *
V.J. DWARKI ET AL.: "Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 1023 - 1027, XP002012406 *

Also Published As

Publication number Publication date
EP0871756A2 (en) 1998-10-21
WO1996033282A2 (en) 1996-10-24
AU5568296A (en) 1996-11-07
JPH11503916A (en) 1999-04-06
CA2216871A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
ZA968382B (en) Vector and method of use for nucleic acid delivery to non-dividing cells
ATE338821T1 (en) STRUCTURAL PROTEIN OF AAV, ITS PRODUCTION AND USE
AU4526193A (en) Binding competent oligomers containing 2', 5' linkages
CA2192215A1 (en) Recombinant aav genome encoding immunodeficiency virus protein
CA2184345A1 (en) Coordinate in vivo gene expression
IL173399A (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
WO2000031235A3 (en) Nucleotide and protein sequences of nogo genes and methods based thereon
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
ATE271612T1 (en) EXPRESSION CASSETTE FOR EXPRESSING ANY GENES IN PLANT SEEDS
BR9206049A (en) Compound, processes for preparing the compound, for sequence specific recognition of a double-stranded polynucleotide, to modulate the expression of a gene in an organism, to treat conditions associated with unwanted protein production in an organism, to induce degradation of DNA or RNA in cells of an organism and to exterminate cells or viruses and pharmaceutical composition
WO1997026337B1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
ATE274593T1 (en) TISSUE OR CELL-SPECIFIC HERPESSIMPLEX VIRUS REPLICATION
EP0472712A4 (en) Novel sequences preferentially expressed in early seed development and methods related thereto
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
EP0568537A4 (en) Genetic modification of endothelial cells.
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
HUP9900808A2 (en) Process for producing nucleoside-5'-phosphate
CA2197286A1 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
HUP9800329A2 (en) Nucleic acid constructs for the cell cycle regulated expression of structural genes
DE19639103A1 (en) DNA construct with inhibitory mutation and corrective mutation
WO1996033282A3 (en) High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
PL324289A1 (en) Encapsulated cells producing virus particles
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2216871

Country of ref document: CA

Ref country code: CA

Ref document number: 2216871

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 531997

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996913061

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996913061

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996913061

Country of ref document: EP